Agio Paper & Inds

AGIOPAPER

Q: Is the debt of Agio Paper & Inds increasing or decreasing?

Yes, The net debt of Agio Paper & Inds is increasing.Latest net debt of Agio Paper & Inds is ₹15.92 Crs as of Sep-25.This is greater than Mar-25 when it was ₹14.91 Crs.

Q: Is Agio Paper & Inds stock expensive?

There is insufficient historical data to gauge this.Latest PE of Agio Paper & Inds is 0

Price

Nano Cap

₹5 Cr.

New to Zerodha? Sign-up for free.

Agio Paper & Industries Limited engages in the manufacture and sale of writing and printing paper in India.The company uses non-conventional raw materials like rice straw and jute waste. The company also manufactures high value-added items like superior grade printing and writing paper, MG poster and computer stationery. In response to the market demand, they have diversified into the field of manufacturing varieties like colour paper, line-o-matic and azure laid paper. Less

Agio Paper & Industries Limited engages in the manufacture and sale of writing and printing paper i… More

Low

3.28

52W Range

High

8.20

Sector PE

14.45

P/B

Div.Yield

ROE

EBIDTA

ROCE

-4.14

EPS

-0.31

New to Zerodha? Sign-up for free.

Get instant stock alerts

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

Coming soon

Summary
Profit & Loss
Balance sheet
Cashflow

Yearly | Quarterly

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

AGIOPAPER
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

AGIOPAPER
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Agios falls after Novo's sickle cell disease drug shows promise in late-stage study

Apr 20, 2026

Updates

** Shares of drugmaker Agios Pharmaceuticals AGIO.O fall 22.8% to $27.14 after rival Novo's NOVOb.CO sickle cell disease drug shows potential

** Danish drugmaker Novo Nordisk says its experimental once-daily oral pill etavopivat for sickle cell disease met the main goals of a late-stage trial

** Last year, AGIO said its sickle cell disease drug met just one of its two main goals in a late-stage study and failed to show a statistically significant reduction in pain

** Meanwhile, Novo says etavopivat showed superior reduction in pain and improvement in haemoglobin response in adults and adolescents with sickle cell disease

** "While we think AGIO could come under pressure off the headline and the competitor update is another threat to AGIO shares potentially climbing back to the $40/sh levels, we believe the majority of the impact of the mixed data has been baked into the stock at this point," say Truist analysts

** We think this development could pressure AGIO shares as Novo Nordisk now expects to submit for regulatory approval in the second-half of this year, introducing near-term competitive risk - J.P. Morgan

** Including session's moves, AGIO down 1.2% YTD

(Reporting by Sneha S K)

(([email protected];))

Updates

** Shares of drugmaker Agios Pharmaceuticals AGIO.O fall 22.8% to $27.14 after rival Novo's NOVOb.CO sickle cell disease drug shows potential

** Danish drugmaker Novo Nordisk says its experimental once-daily oral pill etavopivat for sickle cell disease met the main goals of a late-stage trial

** Last year, AGIO said its sickle cell disease drug met just one of its two main goals in a late-stage study and failed to show a statistically significant reduction in pain

** Meanwhile, Novo says etavopivat showed superior reduction in pain and improvement in haemoglobin response in adults and adolescents with sickle cell disease

** Including session's moves, AGIO down 1.2% YTD

(Reporting by Sneha S K)

(([email protected];))

Events:

Quarterly Results

Announcement Date

Jan 31, 2026

Quarterly Results

Announcement Date

Nov 14, 2025

Annual Report

Announcement Date

Aug 30, 2025

Annual Report

Announcement Date

Sep 06, 2024

Annual Report

Announcement Date

Sep 05, 2023

Reg. 34 (1) Annual Report.

Announcement Date

Sep 03, 2022

More Nano Cap Ideas

See similar 'Nano' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

AGIOPAPER

Share Price

Financials

Summary

Profit & Loss

Balance sheet

Cashflow

Revenue mix

Product wise

Location wise

Shareholdings

Peers

Forensics

Recent events

News

Corporate Actions

Agios falls after Novo's sickle cell disease drug shows promise in late-stage study

Events:

More Nano Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Agio Paper & Inds do?

Who are the competitors of Agio Paper & Inds?

Is Agio Paper & Inds financially stable compared to its competitors?

Does Agio Paper & Inds pay decent dividends?

How has Agio Paper & Inds allocated its funds?

How strong is Agio Paper & Inds balance sheet?

Is the profitablity of Agio Paper & Inds improving?

Is the debt of Agio Paper & Inds increasing or decreasing?

Is Agio Paper & Inds stock expensive?

Has the share price of Agio Paper & Inds grown faster than its competition?

Is the promoter bullish about Agio Paper & Inds?

Are mutual funds buying/selling Agio Paper & Inds?